Abstract 620P
Background
Cancer constitutes a major burden to global health and the critical role of early diagnosis for cancer management is self-evident. Even though various miRNA-based signatures have been developed, their clinical utilization is limited due to various reasons. In this article, we innovatively developed a signature based on pairwise expression of miRNAs (miRPs) for pan-cancer diagnosis using machine learning approach.
Methods
miRNA spectrum of 15832 patients with 13 different cancers from 10 cohorts were analyzed. 15148 patients were divided into training, validation, and test sets with a ratio of 7:2:1, while 648 patients were utilized as external test. Pairwise comparison was performed to generate miRP score, defined by the comparison between two miRNAs, in training set. Five different machine-learning (ML) algorithms (XGBoost, SVM, RandomForest, LASSO, and Logistic) were adopted for signature construction. The best ML algorithm and the optimal number of miRPs included were identified using AUC and youden index in validation. Performance of the ideal model was evaluated in test and external set based on AUC, Youden index, positive predictive value (PPV), negative predictive value (NPV), sensitivity, specificity, and accuracy. The AUC of entire cohorts was compared to previously published 25 signatures.
Results
The Random Forest approach including 31 miRPs (31-miRP) outperformed others and was retained for further evaluation. The AUC of 31-miRP ranges 0.980-1.000 in different set. Remarkably, 31-miRP exhibited advantages in differentiating different cancers from normal tissues. Moreover, 31-miRP demonstrate superiorities in detecting early-stage cancers, with AUC ranging from 0.961-0.998. Compared to previously published 25 different signatures, 31-miRP also demonstrated clear advantages. Remarkably, 31-miRP also exhibited promising capabilities in differentiating cancers from corresponding benign lesions.
Conclusions
The 31-miRP exhibited outstanding diagnostic performance, characterized by high accuracy and sensitivity, thereby holding potential as a reliable tool for cancer diagnosis at early stage. Nevertheless, its effectiveness still warrants further investigation in real-world setting in future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
CAMS Innovation Fund for Medical Sciences (No.2021-I2M-1-050); National Natural Science Foundation for Young Scientists of China (No. 82203025).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
506P - Intrathoracic progression is still the most dominant failure pattern after first-line chemo-immunotherapy in extensive-stage small-cell lung cancer: Implications for thoracic radiotherapy
Presenter: Byoung Hyuck Kim
Session: Poster Display
Resources:
Abstract
519P - Final results and subgroup analysis of ORIENTAL: A phase IIIB study of durvalumab plus platinum-etoposide in first-line treatment of Chinese patients with extensive-stage small-cell lung cancer (ES-SCLC)
Presenter: Ying Cheng
Session: Poster Display
Resources:
Abstract
520P - Role of atezolizumab in controlling CNS progression in ES-SCLC
Presenter: Yoon Namgung
Session: Poster Display
Resources:
Abstract
521P - Camrelizumab combined with chemotherapy and apatinib as first-line therapy for extensive-stage small cell lung cancer: A phase II, single-arm, exploratory research
Presenter: Yanbin Zhao
Session: Poster Display
Resources:
Abstract
522P - Durvalumab plus etoposide and carboplatin for extensive-stage small cell lung cancer with mild idiopathic interstitial pneumonia
Presenter: Ichiro Nakachi
Session: Poster Display
Resources:
Abstract
523P - Camrelizumab plus apatinib as maintenance treatment in patients with extensive-stage small cell lung cancer who were responding or stable after standard first-line chemotherapy (CAMERA): Results from a single-arm, phase II trial
Presenter: Qi Wang
Session: Poster Display
Resources:
Abstract
524P - Treatment pattern and overall survival by lines of therapy among patients with advanced small cell lung cancer in Taiwan
Presenter: Kelly Huang
Session: Poster Display
Resources:
Abstract
525P - Development of diagnostic prediction score for malignant pleural effusion in lung cancer: MPE-Lung score
Presenter: Chaichana Chantharakhit
Session: Poster Display
Resources:
Abstract
526P - Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
527P - Efficacy of intraventricular chemotherapy with pemetrexed for leptomeningeal metastasis from lung adenocarcinoma: A retrospective study
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract